The pandemic has heightened the need to advance health equity and, at Amgen, we continue to build upon our work to advance policies and practices in support of achieving health equity so that all people have an opportunity to be as healthy as possible. One of our strategic pillars to achieve health equity is to ensure representative product development with the objective to expand access and improve our participation in clinical trials in disease states that disproportionately affect racial and ethnic minorities.
To advance this effort, Amgen created a dedicated team called RISE (Representation in Clinical Research) which is mandated to improve the proportional representation of historically underrepresented populations in our clinical trial programs.
The RISE team has set ambitious objectives to exceed the current industry benchmark for representation in clinical trials in the U.S. within the next three to five years including short, medium, and long-term goals.
We are developing a comprehensive community engagement plan for establishing partnerships with trusted community and faith-based organizations to support execution of our strategy.
We are also working with policymakers by providing input into ongoing legislative efforts in the US aimed at removing barriers and enhancing participation in research.
However, our long-term goal is to ensure that we adopt strategies that can expand representative enrollment globally and work hand in glove with Amgen’s cross-functional partners to drive healthcare equity across the globe.
We look forward to continuing our partnership with BIO and other stakeholders on solutions that will reduce disparities and improve health outcomes.
For more information about Amgen’s RISE program, please go to: https://wwwext.amgen.com/stories/2021/02/inside-amgens-push-for-greater-diversity-in-clinical-trials